Trial Profile
Multiple-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Catheter thrombosis
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 10 Sep 2014 New source identified and integrated (European Clinical Trials Database - EudraCT2010-024597-19).
- 22 Mar 2014 Results presented at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 27 Dec 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.